Literature DB >> 32206846

Local treatment with a polycarbophil-based cream in postmenopausal women with genitourinary syndrome of menopause.

Tipatai Yodplob1, Kun Sirisopana1, Mutita Jongwannasiri1, Pokket Sirisreetreerux1, Wit Viseshsindh2, Wachira Kochakarn1.   

Abstract

INTRODUCTION AND HYPOTHESIS: Genitourinary syndrome of menopause (GSM) is a common problem associated with lower urinary tract and gynecological symptoms due to the decrease in estrogen production in postmenopausal women. Topical estrogen therapy is shown to improve these symptoms; nonetheless, there are limited data on the efficacy of nonhormonal moisturizers in these patients.
METHODS: A prospective cohort study was conducted to compare the symptoms of GSM before and after treatment with a polycarbophil-based cream in 42 women. The quality of life (QoL) and sexual scores were obtained from the Thai version of the International Consultation on Incontinence Modular Questionnaire-Lower Urinary Tract Symptoms (ICIQ-LUTS) along with uroflow measurements before and 4 and 12 weeks after treatment.
RESULTS: Significant improvements in ICIQ-LUTSqol scores were observed after 4 weeks (9.38 ± 7.47 vs 6.76 ± 5.77; p = 0.017) and 12 weeks (10.03 ± 7.49 vs 5.97 ± 4.02; p = 0.002) when compared with the baseline values before treatment. The ICIQ-LUTS sexual scores were also improved after treatment at 4 weeks (2.29 ± 2.26 vs 0.88 ± 1.34; p < 0.001) and 12 weeks (2.13 ± 2.22 vs 0.42 ± 0.81; p < 0.001) compared with the baseline scores. No differences in ICIQ-LUTSqol and sexual scores were observed between the 4- and 12-week treatment groups.
CONCLUSION: The polycarbophil-based cream improved the overall LUTS and sexual symptoms in the patients with GSM, thus indicating that the nonhormonal polycarbophil-based cream may prove effective for the treatment for women with this condition.

Entities:  

Keywords:  Genitourinary syndrome of menopause; Polycarbophil-based cream; Vaginal dryness; Vaginal lubricant; Vaginal moisturizer; Vulvovaginal atrophy

Year:  2020        PMID: 32206846      PMCID: PMC7838131          DOI: 10.1007/s00192-020-04282-9

Source DB:  PubMed          Journal:  Int Urogynecol J        ISSN: 0937-3462            Impact factor:   2.894


  2 in total

1.  Efficacy of vaginal use of topical estriol in postmenopausal women with urogenital atrophy.

Authors:  A C S Chuery; N M de Góis Speck; K F Q de Moura; P N Belfort; C Sakano; J C L Ribalta
Journal:  Clin Exp Obstet Gynecol       Date:  2011       Impact factor: 0.146

2.  Postmenopausal vulvovaginal atrophy (VVA) is positively improved by topical hyaluronic acid application. A prospective, observational study.

Authors:  M Origoni; C Cimmino; G Carminati; E Iachini; C Stefani; S Girardelli; S Salvatore; M Candiani
Journal:  Eur Rev Med Pharmacol Sci       Date:  2016-10       Impact factor: 3.507

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.